HR 2831 United States House · 117th Congress

Prompt Approval of Safe Generic Drugs Act

Summary
Prompt Approval of Safe Generic Drugs Act This bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a drug even if the drug's labeling lacks certain safety information. Specifically, an abbreviated application for approval of a generic drug shall not be ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's exclusivity protections. Similarly, a drug that is approved under this bill shall not be considered mislabeled for lacking such safety information. Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug. For any drug approved under this bill, the FDA shall require the drug's labeling to include any safety information that is necessary to assure safe use.
Bill status in committee 1 of 4 stages cleared
Introduction
Apr 2021
Committee Review
Floor Vote
President
Introduced Apr 26, 2021 Last action Apr 27, 2021
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
3
Key actions
0
Committee
2
Apr 27, 2021
Committee
Referred to the Subcommittee on Health.
lower
Apr 26, 2021
Committee
Referred to the House Committee on Energy and Commerce.
lower
Apr 26, 2021
Introduced
Introduced in House
lower
1 primary · 0 co-sponsors

Sponsors

Role
Legislator
Party
State
District
P
Photo of Nanette Diaz Barragán
Nanette Diaz Barragán
DDemocratic
CA
44